Description
5,6-Methylenedioxy-2-aminoindane is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic and highly selective serotonin releasing agent in vitro and produces entactogen effects in humans.
Chemically, MDAI is very similar to 3,4-methylenedioxyamphetamine (MDA), which is principally used as a recreational drug, the main difference being the existence of a bond between the alpha-methyl group of the alkylamino amphetamine side chain and the benzene nucleus (Indane ring).
Reviews
There are no reviews yet.